Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.58 |
| ▸ | KDR | P35968 | 7/20 | 0.56 |
| ▸ | AXL | P30530 | 3/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | MERTK | Q12866 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26074436 | 0.92 | MET (0.59) | METKDRAXLRETKIT | |
| SCHEMBL16136597 | 0.86 | MET (0.67) | METKDRAXLRETKIT | |
| SCHEMBL11565621 | 0.84 | KCNQ3 (0.47) | METKDR | |
| SCHEMBL26077946 | 0.83 | GLA (0.54) | METKDRAXLRETKIT | |
| SCHEMBL16381016 | 0.83 | MET (0.59) | METKDRAXLRETKIT | |
| SCHEMBL23136513 | 0.81 | MET (0.51) | METKDRAXLRETKIT | |
| SCHEMBL16069961 | 0.81 | MET (0.58) | METKDRAXLRETKIT | |
| SCHEMBL9609152 | 0.80 | MET (0.58) | METKDRAXLRETKIT | |
| SCHEMBL24413668 | 0.80 | MET (0.89) | METKDRAXLRETKIT | |
| SCHEMBL13760326 | 0.80 | MET (0.57) | METKDRAXLRETKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | MET 49/4885KDR 209/4885AXL 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.